Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted. Less than ...

For further information on Bright Minds, investors should review the Company’s annual Form 40-F filing with the United States ...

Bright Minds Biosciences (NASDAQ: DRUG), a little-known biotech company, became the talk of the market yesterday after its stock skyrocketed by 1,445% in a single trading session. Typically trading ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing ...

Bright Minds Biosciences announced a non-brokered private placement with expected gross proceeds of $35 million. The company's stock is currently trading with a session volume of about 10.6 million.

BrightMinds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) today closed its recently announced ...